MNPR - Monopar Therapeutics Inc
39.1
0.320 0.818%
Share volume: 12,120
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$38.78
0.32
0.01%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-09-2024 | 08-10-2023 | 11-09-2023 | 11-08-2024 | 05-09-2024 | 08-09-2024 | 11-08-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 2.525 M | 2.328 M | 2.066 M | 1.912 M | 1.723 M | 1.789 M | 1.575 M | |
| Selling general and admin | 871.675 K | 733.496 K | 749.474 K | 876.397 K | 757.281 K | 657.806 K | 590.624 K | |
| Research and development | 1.653 M | 1.595 M | 1.317 M | 1.036 M | 966.110 K | 1.131 M | 984.278 K | |
| Total expenses | 2.525 M | 2.328 M | 2.066 M | 1.912 M | 1.723 M | 1.789 M | 1.575 M | |
| -7.80% | -11.26% | -7.45% | -9.86% | 3.79% | -11.96% | |||
| Operating income | -2.525 M | -2.328 M | -2.066 M | -1.912 M | -1.723 M | -1.789 M | -1.575 M | |
| Ebit | -2.525 M | -2.328 M | -2.066 M | -1.912 M | -1.723 M | -1.789 M | -1.404 M | |
| Pretax income | -2.435 M | -2.200 M | -1.954 M | -1.814 M | -1.641 M | -1.715 M | -1.304 M | |
| -9.63% | -11.19% | -7.16% | -9.52% | 4.51% | -23.96% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -2.435 M | -2.200 M | -1.954 M | -1.814 M | -1.641 M | -1.715 M | -1.304 M | |
| 9.63% | 11.19% | 7.16% | 9.52% | -4.51% | 23.96% |
